Navigation Links
Histogen’s Composition for Hair Growth Receives US Patent
Date:9/17/2013

San Diego, CA (PRWEB) September 17, 2013

Histogen, Inc., a regenerative medicine company developing innovative therapies based on the products of cells grown under simulated embryonic conditions, today announced that the United States Patent & Trademark Office has issued patent 8,535,913, entitled “Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells”.

The patent, which is the fourth US patent issued to the Company, covers the liquid composition of proteins and cofactors that is secreted by multipotent stem cells through Histogen’s technology process, and the method of administering that composition to stimulate hair growth. Histogen’s Hair Stimulating Complex (HSC), covered by this new patent, is in clinical development as an injectable treatment for male pattern and female diffuse hair loss.

“We are extremely pleased that HSC, and future hair restoration treatments using this technology, are now bolstered by a US patent,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “At a time when the industry continues to uncover information about how cell-signaling results in hair growth and maintenance, patent protection for our unique composition of proteins and growth factors is of great benefit to Histogen and its future partners.”

Several factors critical to hair growth such as follistatin, VEGF and KGF, are present in HSC, and their secretion by the cells is stimulated by low oxygen and special culture conditions utilized by Histogen. The conditions under which the cells are manufactured not only upregulates genes associated with hair growth, but induces significantly increased production of these critical factors than seen with traditional culture conditions.

In two Company-sponsored clinical trials, HSC has resulted in statistically significant increases across hair growth parameters, including hair count, density and thickness. In addition, the treatment has shown efficacy in difficult-to-treat patient groups, including women, older subjects and those with temporal recession region hair loss. Histogen looks forward to progressing HSC to the next clinical stage, and to further analyzing its newly-patented composition.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11129502.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
3. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
4. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
5. RSB Spine, LLC Announces 2011 Revenue Growth
6. ERT Launches New Website to Support Significant Commercial Growth
7. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
8. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
10. Carbon nanotubes can double growth of cell cultures important in industry
11. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2019)... (PRWEB) , ... August 29, 2019 , ... ... year to teach in the Sustainable Medicines in Africa program, which includes a ... take place in Arusha, Tanzania September 2nd through 13th, 2019. Topics to ...
(Date:8/23/2019)... Wis. (PRWEB) , ... August 22, 2019 , ... The ... some of the most harmful germs and pathogens on hard surfaces including E. Coli, ... leaves behind no chemical residues. For more information, visit the product page at rovingblue.com ...
(Date:8/14/2019)... ... August 13, 2019 , ... Chata ... phases for QC laboratories. After gaining a few significant clients, Lifecycle purchased the ... a valued supplier of manufacturing processing solutions, including reagents for tissue processing. Chata ...
(Date:8/6/2019)... FARMINGTON, Conn. (PRWEB) , ... August 06, 2019 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Biome’s microbiome kits and other products to companies and research organizations in Australia, ...
Breaking Biology Technology:
(Date:8/23/2019)... ... , ... R121 solidifies its place within The Planet Group ... with the name change, this rebranding includes a comprehensive redesign of the company’s ... brand that blended our core foundation of genuine ‘one-to-one’ relationships with Planet’s global ...
(Date:8/19/2019)... N.J. (PRWEB) , ... August 19, 2019 , ... ... have characterized tissues through the use of ultra-thin two dimensional slices which are ... can be highly limited for complex tissues and complicated features such as vasculature ...
(Date:8/14/2019)... ... August 14, 2019 , ... An upcoming episode ... in microbiome therapeutics are helping to promote normal immune function in order to ... will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops microbiome therapeutics in ...
Breaking Biology News(10 mins):